Stem cell transplant to stop anti-rejection drugs after kidney transplant
Part of Immune system & allergy clinical trials.
This study tries to use a stem cell transplant from your original kidney donor to help your body accept the kidney without needing lifelong anti-rejection drugs. You must have a perfectly matched sibling donor who is still available.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 or older.
- You received a kidney transplant from a sibling who is a perfect HLA match (like a tissue-type twin).
- Your sibling donor is still alive and able to donate stem cells.
- Your kidney has never been rejected (no acute or chronic rejection).
- You do not have HIV, Hepatitis B, or Hepatitis C.
- You have not had cancer (except minor skin cancers).
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This Phase 1 study tests a treatment plan (including rabbit medicine and a low dose of radiation) meant to help the new kidney “take” and work longer. It also includes a kidney-from-deceased-donor process and checks how safely the treatment works in people with end-stage kidney disease.
This trial tests a way to help your body accept your liver transplant without needing lifelong anti-rejection drugs. It uses your living donor's stem cells to train your immune system to not attack the new liver.
This trial tests a combination of low-dose radiation, chemotherapy, and donor immune cells to help your body accept a living donor kidney without long-term anti-rejection drugs.
This trial tests a new combination of radiation and antibody treatment for people receiving a liver transplant at Stanford. The goal is to help your new liver last longer by training your immune system to accept it while reducing the need for lifelong anti-rejection drugs.
This early-phase trial tests a stem cell transplant from a donor who is an extremely close match, given to people who are about to receive a kidney transplant from the same donor. The goal is to improve how well the new kidney works by resetting the immune system to better accept the transplant.
This study tests a combined approach for kidney transplant patients: standard living-donor kidney transplant plus an added “stem cell” component taken from the same sibling donor. It aims to improve transplant outcomes by trying to better control the immune response and reduce complications.
Hear when a new Immune Tolerance trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.